Overview
Mucopolysaccharidosis type 4A (MPS 4A), also known as Morquio A syndrome or Morquio disease type A, is a rare inherited metabolic disorder. It belongs to a group of conditions called lysosomal storage diseases. In this condition, the body cannot produce enough of an enzyme called N-acetylgalactosamine-6-sulfatase (GALNS). This enzyme is needed to break down certain complex sugars called glycosaminoglycans (GAGs), specifically keratan sulfate and chondroitin-6-sulfate. When these sugars build up in the body's cells, they cause progressive damage, especially to bones, cartilage, and connective tissues. The hallmark features of Morquio A syndrome include short stature, skeletal abnormalities, and joint problems. Children often appear normal at birth but begin showing signs in early childhood. Common problems include a short trunk, knock-knees, a prominent chest (pectus carinatum), spinal abnormalities, and loose joints. The neck can be particularly affected, with instability of the upper spine that can be dangerous. Unlike some other types of MPS, intelligence is usually normal in Morquio A syndrome. However, the disease can also affect the heart, eyes, ears, and breathing. Treatment options have expanded in recent years. An enzyme replacement therapy called elosulfase alfa (Vimizim) was approved by the FDA in 2014 and helps slow the progression of the disease. Supportive care including orthopedic surgeries, physical therapy, and monitoring of the heart and airways remain essential parts of management. Hematopoietic stem cell transplant is being explored but is not yet standard treatment for this type of MPS.
Also known as:
Key symptoms:
Short stature with a short trunkKnock-knees (legs bowing inward)Prominent or pigeon-shaped chestSpinal curvature or abnormalitiesLoose and overly flexible jointsInstability of the upper neck bonesWaddling walk or difficulty walkingClouding of the cornea in the eyesHearing lossHeart valve problemsBreathing difficultiesFrequent ear infectionsDental abnormalities including thin enamel and widely spaced teethEnlarged liverReduced endurance and fatigue
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
FDA & Trial Timeline
1 eventUniversity of California, San Francisco — PHASE1, PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableVIMIZIM
VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Mucopolysaccharidosis type 4A.
Community
No community posts yet. Be the first to share your experience with Mucopolysaccharidosis type 4A.
Start the conversation →Latest news about Mucopolysaccharidosis type 4A
No recent news articles for Mucopolysaccharidosis type 4A.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is my child's form of Morquio A, and what can we expect over time?,Is the cervical spine (neck) stable, and when should we consider spinal surgery?,Should we start enzyme replacement therapy (Vimizim), and what are the benefits and risks?,How often do we need imaging of the spine, heart, and other organs?,What activities should we avoid to protect the neck and spine?,Are there any clinical trials for new treatments that we should consider?,What precautions are needed if my child ever needs surgery or anesthesia?
Common questions about Mucopolysaccharidosis type 4A
What is Mucopolysaccharidosis type 4A?
Mucopolysaccharidosis type 4A (MPS 4A), also known as Morquio A syndrome or Morquio disease type A, is a rare inherited metabolic disorder. It belongs to a group of conditions called lysosomal storage diseases. In this condition, the body cannot produce enough of an enzyme called N-acetylgalactosamine-6-sulfatase (GALNS). This enzyme is needed to break down certain complex sugars called glycosaminoglycans (GAGs), specifically keratan sulfate and chondroitin-6-sulfate. When these sugars build up in the body's cells, they cause progressive damage, especially to bones, cartilage, and connective t
How is Mucopolysaccharidosis type 4A inherited?
Mucopolysaccharidosis type 4A follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Mucopolysaccharidosis type 4A typically begin?
Typical onset of Mucopolysaccharidosis type 4A is childhood. Age of onset can vary across affected individuals.
Are there clinical trials for Mucopolysaccharidosis type 4A?
Yes — 1 recruiting clinical trial is currently listed for Mucopolysaccharidosis type 4A on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Mucopolysaccharidosis type 4A?
6 specialists and care centers treating Mucopolysaccharidosis type 4A are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Mucopolysaccharidosis type 4A?
1 patient support program are currently tracked on UniteRare for Mucopolysaccharidosis type 4A. See the treatments and support programs sections for copay assistance, eligibility, and contact details.